AU5547501A - Method of reducing side effects of chemotherapy in cancer patients - Google Patents

Method of reducing side effects of chemotherapy in cancer patients

Info

Publication number
AU5547501A
AU5547501A AU5547501A AU5547501A AU5547501A AU 5547501 A AU5547501 A AU 5547501A AU 5547501 A AU5547501 A AU 5547501A AU 5547501 A AU5547501 A AU 5547501A AU 5547501 A AU5547501 A AU 5547501A
Authority
AU
Australia
Prior art keywords
chemotherapy
side effects
cancer patients
reducing side
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5547501A
Other languages
English (en)
Inventor
Alfred R Rudolph
Vincent Chung-Yin Tam
Maggie Jie Quan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of AU5547501A publication Critical patent/AU5547501A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU5547501A 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients Pending AU5547501A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/561,917 US6462017B1 (en) 2000-05-01 2000-05-01 Method of reducing side effects of chemotherapy in cancer patients
PCT/US2001/012696 WO2001082949A2 (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients

Publications (1)

Publication Number Publication Date
AU5547501A true AU5547501A (en) 2001-11-12

Family

ID=24244042

Family Applications (2)

Application Number Title Priority Date Filing Date
AU5547501A Pending AU5547501A (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients
AU2001255475A Ceased AU2001255475B2 (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001255475A Ceased AU2001255475B2 (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients

Country Status (9)

Country Link
US (1) US6462017B1 (https=)
EP (1) EP1357935B1 (https=)
JP (1) JP2004501870A (https=)
CN (1) CN100441221C (https=)
AT (1) ATE348630T1 (https=)
AU (2) AU5547501A (https=)
CA (1) CA2407238C (https=)
DE (1) DE60125417D1 (https=)
WO (1) WO2001082949A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
PL377376A1 (pl) 2002-11-25 2006-02-06 Sciclone Pharmaceuticals, Inc. Sposoby ochrony przed uszkodzeniem przez promieniowanie z użyciem Ó-tymozyny
JP2006213645A (ja) * 2005-02-03 2006-08-17 Hokkaido Univ ゲラニルゲラニルアセトンと抗癌剤とを組み合わせてなる医薬
JP5044150B2 (ja) * 2005-08-05 2012-10-10 Ｔｏｔｏ株式会社 光照射により薬効を消失させる医薬二酸化チタン複合材
US20070292392A1 (en) * 2006-06-15 2007-12-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
EP2141995B1 (en) * 2007-03-27 2014-11-05 Perscitus Biosciences, LLC Compositions and their uses in protecting cells from toxic exposures
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
US20100317583A1 (en) * 2007-12-14 2010-12-16 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
CA2753844A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
US20140322320A1 (en) * 2013-04-24 2014-10-30 Uday Saxena Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
WO2016190780A1 (en) 2015-05-22 2016-12-01 Dmitry Dmitrievich Genkin Extracellular dna as a therapeutic target in neurodegeneration
EP3368064B1 (en) * 2015-10-29 2021-05-19 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of anti-cancer chemotherapy
CN107137684A (zh) * 2017-05-23 2017-09-08 山西中医学院 一种用于胃肠疾病的药物组合物及其制备方法和用途
FR3074042A1 (fr) 2017-11-29 2019-05-31 Galderma Research & Development Kit pour son utilisation dans la prevention et/ou le traitement des effets secondaires lies a une therapie anticancereuse
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료
CN109820859A (zh) * 2019-04-09 2019-05-31 上海市计划生育科学研究所 醋酸诺美孕酮在制备预防或治疗呕吐或改善恶病质的药物中的应用
IT202300020361A1 (it) 2023-10-03 2025-04-03 Blue Hydrogen Science S R L Nuovi utilizzi di soluzioni acquose ad elevata concentrazione di idrogeno

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US527393A (en) * 1894-10-09 Busy-test for multiple switchboards
US5273963A (en) 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide

Also Published As

Publication number Publication date
EP1357935A2 (en) 2003-11-05
CN100441221C (zh) 2008-12-10
CN1529614A (zh) 2004-09-15
WO2001082949A3 (en) 2003-08-28
DE60125417D1 (de) 2007-02-01
HK1060280A1 (en) 2004-08-06
JP2004501870A (ja) 2004-01-22
AU2001255475B2 (en) 2006-01-05
ATE348630T1 (de) 2007-01-15
EP1357935B1 (en) 2006-12-20
CA2407238A1 (en) 2001-11-08
CA2407238C (en) 2012-03-13
US6462017B1 (en) 2002-10-08
WO2001082949A9 (en) 2004-04-22
WO2001082949A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU5547501A (en) Method of reducing side effects of chemotherapy in cancer patients
WO2004045523A3 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
SG131943A1 (en) Specific binding agents to hepatocyte growth factor
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
YU37301A (sh) Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
AU5392001A (en) Taci as an anti-tumor agent
WO2007123995A3 (en) Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
WO2008030538A3 (en) Cancer stem cell-targeted cancer therapy
ZA200703396B (en) Pegylated Liposomal Doxorubicin in combination with Ecteinascidin 743
DE60227244D1 (de) Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
WO2008128191A3 (en) Oral cephalotaxine dosage forms
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2005009363A3 (en) Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies
GB9917416D0 (https=)
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
MY125855A (en) Treatment of diabetes with a thiazolidinedione and sulphonylurea
BR0301701A (pt) Método para prevenir a diminuição de uma quantidade de leite de mama em um mamìfero
MXPA06009711A (es) Uso de carboxipeptidasa g para combatir la toxicidad de antifolato.